Generic Drug News and Research RSS Feed - Generic Drug News and Research

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.
Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

New research from CVS Health finds starting a new diabetes patient on metformin, a generic oral diabetes medicine that helps control blood sugar levels, reduced the need to add on additional treatments to control the condition over time. Although there are many classes of oral diabetes medications, there has historically been little evidence available on the comparative effectiveness of treatments to help patients and providers select an initial diabetes therapy. [More]
MPI Research announces acquisition of Jasper Clinical Research & Development

MPI Research announces acquisition of Jasper Clinical Research & Development

MPI Research today announced it has acquired the assets of Kalamazoo, Mich.-based Jasper Clinical Research & Development, Inc. Jasper is a respected clinical research organization that provides early-stage human clinical testing of promising new drugs, and is well known to pharmaceutical and biotechnology companies worldwide. [More]
Stiff rise in generic drug prices prompts probe by members of Congress

Stiff rise in generic drug prices prompts probe by members of Congress

The prices have increased by more than 1,000 percent for some of the drugs. In other news about treatments, a study finds robotic surgery may not improve care for ovarian problems and the National Cancer Institute laments that insurers' concerns about cost are keeping some patients from proton therapy trials. [More]
Doctors, hospitals went digital, but still can't share records

Doctors, hospitals went digital, but still can't share records

After spending billions to switch from paper to digital records -- much of it taxpayer subsidized through the economic stimulus package -- providers say the systems often do not share information with competitors. [More]
Drugmakers boost generic drug prices

Drugmakers boost generic drug prices

A big increase in generic drug prices is forcing some patients to go without, reports CBS Boston. Meanwhile, U.S. News & World Report teases out some of the reasons for the slowdown in health care costs. [More]
IGI Laboratories acquires regulatory rights for 18 drug products from AstraZeneca

IGI Laboratories acquires regulatory rights for 18 drug products from AstraZeneca

IGI Laboratories, Inc., a New Jersey based specialty generic pharmaceutical company, today announced it has acquired the regulatory rights and related documents and records for 18 drug products from AstraZeneca, 17 of which were marketed. [More]

Demand for $84,000 hepatitis C drug slows

Health care providers may be waiting for other, soon-to-be-released drugs to treat hepatitis C. Also, an Indian pharmaceutical company faces Justice Department questions on pricing data for Medicaid. [More]
Gilead to boost price of new hepatitis c drug

Gilead to boost price of new hepatitis c drug

Gilead Sciences says its next generation drug to combat hepatitis C, slated to launch next month, will be more expensive than $1,000-a-pill Sovaldi, in part because the new treatment will be shorter and simpler. Gilead also struck a deal with Indian generic drugmakers to sell lower-cost versions of Sovaldi in poor countries. [More]
TWi Pharmaceuticals obtains final approval from FDA for megestrol acetate 125mg/ml oral suspension

TWi Pharmaceuticals obtains final approval from FDA for megestrol acetate 125mg/ml oral suspension

TWi Pharmaceuticals, Inc. today announced that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for megestrol acetate 125mg/ml oral suspension, the generic equivalent to Par Pharmaceutical's Megace ES. [More]
Study on cancer care offers model for possible lower spending on treatment

Study on cancer care offers model for possible lower spending on treatment

The study, however, raised some questions because while it cut costs by a third and showed no decline in patient health, the spending on chemotherapy medications rose. [More]
First Edition: June 9, 2014

First Edition: June 9, 2014

Today's headlines include a status report on GOP discussions and debate over plans to replace the health law as well as coverage of emerging legislation to override the Supreme Court's Hobby Lobby decision. [More]
USA witnesses dramatic slowdown in health spending growth over last decade

USA witnesses dramatic slowdown in health spending growth over last decade

Growth in health expenditure in the USA slowed dramatically between 2000 and 2011, bringing the growth rate of the country’s health budget in line with other high-spending countries, according to new research published in The Lancet as part of a new Series, The health of Americans. [More]

Concerns rise about delays in getting generic drugs to market

PBS NewsHour explores concerns that settlements on patents for drugs sometimes delay the generic version getting to consumers. [More]
Generic drug delays cost U.S. payers millions

Generic drug delays cost U.S. payers millions

Problems surrounding an Indian company's launch of generic versions of three blockbuster drugs have preserved millions in revenue for the brand-name makers, reports The Wall Street Journal. [More]
Walgreens reports May sales of $6.57 billion

Walgreens reports May sales of $6.57 billion

Walgreens had May sales of $6.57 billion, an increase of 6.0 percent from $6.19 billion for the same month in fiscal 2013. [More]
Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities. [More]
U.S. Court awards Teva favorable decision for generic Celebrex

U.S. Court awards Teva favorable decision for generic Celebrex

Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day "first-to-file" exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules. [More]
TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR- will be presented at the American Thoracic Society (ATS) 2014 International Conference in San Diego on May 18, 2014. [More]
First Edition: May 16, 2014

First Edition: May 16, 2014

Today's headlines include reports about the Indiana governor's alternative plan to expand Medicaid. Kaiser Health News staff writer Sarah Varney, working in collaboration with PBS Newshour, reports: "Men and women involved in the criminal justice system are more likely to be sicker than the general population, with higher rates of diabetes, hypertension, depression, mood disorders and alcohol and drug addiction. [More]
Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Teva Pharmaceutical Industries Ltd., today announced that COPAXONE (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry. [More]